Objective: We have previously shown that cardiac-directed expression of adenylycyclase type VI (AC ) increases heart function in VI transgenic mice, and improves heart function and survival in murine cardiomyopathy. However, a potential problem of crossbreeding paradigms that use lines with two constitutively active transgenes is that results can be obfuscated by interactions between transgenes during growth and development. Methods: To develop a model that could be used subsequently to address this generic problem, transgenic mice with tetracycline (tet)-regulated cardiac-specific expression of AC were generated. In this transgenic strain, the VI expression of a tet-controlled transactivator (tTA) was under control of the rat a-myosin heavy chain promoter. Expression of the AC VI gene was driven by a tet-response element (TRE) and a minimal CMV promoter. Results: Homogenates of hearts showed no change in AC protein content during tet suppression (doxycycline), confirming successful suppression of transgene expression. Removal of tet VI suppression for 10 days was associated with a 10-fold increase in cardiac AC protein content. A similar increase in mRNA was VI observed (Northern blot analysis). The estimated half-life of newly synthesized cardiac AC protein was 2-3 days. Isolated cardiac VI myocytes from animals that had tet-suppression removed for 10 days showed increased cAMP production in response to forskolin stimulation (Transgene Off: 1566 fmol / mg; Transgene On: 39614 fmol / mg; n55 each group; P50.004) and also to isoproterenol stimulation (Transgene Off: 2065 fmol / mg; Transgene On: 31612 fmol / mg; n55 each group; P50.035) and hearts isolated from these animals showed marked increased left ventricular peak dP/dt in response to dobutamine stimulation (P50.009) indicating that inducible cardiac AC is functionally coupled and recruitable. Conclusion: We have generated transgenic mice with controlled cardiac-specific VI expression of AC , provided detailed information regarding the kinetics of transgene expression and suppression and estimated the VI half-life of cardiac AC protein to be 2-3 days. Finally, we have shown, for the first time, that controlled cardiac-directed expression of VI a transgene can increase cardiac myocyte cAMP generation and left ventricular contractile function. 
development may prevent the index disease from ever the Guide for the Care and Use of Laboratory Animals developing in the first place. Furthermore, one can never published by the US National Institutes of Health (NIH be certain that a favorable outcome is not due to interacPublication 85-23, revised 1996). tions between two transgenes that have little to do with a treatment effect per se. Preventing a disease state from 2 .1. Generation of transgenic mice ever manifesting is, admittedly, very different from treating a disease already present.
To generate mice with cardiac-directed regulatable An approach with higher fidelity to clinical treatment of expression of AC , a murine AC cDNA was subcloned VI VI disease would be the transfer of a therapeutic gene when downstream of a minimal CMV promoter controlled by a signs of heart failure, for example, are already present. tetracycline response element (TRE.CMV.min). Alternatively, this could be achieved by regulated expres-TRE.CMV.min was excised from a pRetro-On vector sion of a therapeutic transgene. Exogenous control of (Clontech, Palo Alto, CA, USA) and both TRE.CMV.min transgene expression has been previously achieved in and murine AC cDNA were subcloned into pBluescript VI transgenic mice by using tetracycline (tet) transactivator or II SK vector (Stratagene, San Diego, CA, USA). A 7-kb suppressor systems [2] [3] [4] [5] . However, the utility of these fragment containing the expression cassette of the consystems to provide a regulated means to increase cardiac struct was used for microinjection. Pronuclear injection myocyte function per se has not been demonstrated.
was carried out in the transgenic mouse facility at UniTaking advantage of both the tight regulation provided versity of California, San Diego according to standard by the tet-off system in transgenic mice and cardiactechniques into mouse ovum (strain C57B6 / F1). Founder specific expression provided by the a-myosin heavy chain mice were identified by polymerase chain reaction (PCR) (a-MHC) promoter, Yu et al. developed a transgenic of genomic DNA prepared from tail tips. The tTA mice mouse in which transgene expression was tissue-specific (strain B6 / CBAF1, provided by Dr. G.I. Fishman) express and regulatable [5] . They crossed transgenic mice harbora tetracycline-controlled transactivator (tTA) under the ing the tet-controlled transactivator (tTA) gene under the control of a 2.9-kb rat a-myosin heavy chain promoter [5] . control of the a-MHC promoter (for cardiac-specific
The animals of line 6, aged 3-6 months, were used for this expression of tTA) with a transgenic line carrying a study. reporter gene under the control of the tTA-responsive promoter (for tet-inducibility). They demonstrated that in 2 .2. Polymerase chain reaction (PCR) analysis the double-transgenic offspring, the reporter gene was significantly induced in cardiac tissue after tetracycline
The AC transgene was identified with primers from VI withdrawal and displayed very little background expres-CMV.min promoter region (CMVP: 59-sion in the presence of tetracycline. However, their study GCAGAGCTCGTTTAGTGAAC-39) and the AC gene VI failed to prove that regulated expression of a cardiac (AC P1: 59-CAGGAGGCCACTAAACCATGAC-39) re-VI transgene could alter cardiac function. Using a similar sulting in a 224-bp PCR product. The tTA transgene was system to obtain regulated and cardiac-directed expression identified using identical primers as described by Yu et al. of a modified Gi-coupled receptor, Redfern et al. were able [5] . To determine whether cardiac AC mRNA content V to induce cardiomyopathy [6] . However, no one has was changed by increased cardiac AC expression, re-VI achieved a regulated means to increase cardiac function. verse transcription and the polymerase chain reaction (RTIn the current study we have generated transgenic mice PCR) was used on samples of heart obtained from transthat express murine AC in a cardiac-specific and regulatgenic mice with constitutive cardiac-directed expression of as described previously [7] . Total RNA from samples of induced cardiac AC protein content to be 100% and then VI heart was extracted, separated on a 1.0% formaldehydeexamined the amount remaining 1, 2 and 3 days after agarose gel, and transferred onto a nylon membrane. clonal antibody recognizing AC and AC proteins as described previously [7] . Cardiac myocytes were iso-
(Santa Cruz Biosciences) was used in immunoblotting lated after intracoronary perfusion and digestion of the conducted on cardiac homogenates. Total cardiac memheart with perfusion medium (Joklik-modified minimum brane protein (100 mg) was separated on 7.0% PAGE and essential medium with 10 mM Na-HEPES, 30 mM taurine, transferred to a nitrocellulose membrane. The AC pro-2 mM carnitine, and 2 mM creatine; pH 7.36) and VI tein was detected by incubating the membrane with anticollagenase (Worthington Type II, 358 I.U. / mg, 1 mg / AC /AC primary antibody followed by a goat antiml). Isolated cardiac myocytes were stimulated (10 min)
rabbit IgG horseradish peroxidase conjugate (Gibco-BRL with forskolin (10 mM) or isoproterenol (10 mM). Cyclic Life Technology).
AMP was extracted from cells using 7.5% ice-cold trichloroacetic acid and measured by radioimmunoassay 2 .4. Regulated expression of transgene (Amersham Life Science).
To repress tTA-dependent transactivation, the water 2 .8. Left ventricular contractile function supply included doxycycline (0.2 mg / ml) and 2% sucrose. To induce the expression of transgene AC , doxycycline Cardiac function in response to adrenergic stimulation VI was withdrawn from the water and animals killed 10 days was assessed in isolated perfused hearts (LV end-diastolic 21 later. Doxycycline inhibits matrix metalloproteinases pressure 10 mmHg; 1.7 mM ionized Ca ) using an (MMP), which can be associated with alterations in left intraventricular balloon catheter to measure isovolumic LV ventricular geometry [8] . We found no adverse effects of pressure as previously described [9] . Dobutamine (0.1, 1 doxycycline on cardiac structure or function when adand 10 mM) was delivered in bolus doses at 5-min ministered to mice for as long as 15 still be detectable after reinstituting transgene suppression with doxycycline-an experiment that would provide data regarding the half-life of newly synthesized AC . Trans- cardiac AC mRNA and protein were increased by day 4 suppressed 1 day after doxycycline addition (Fig. 4) . Of VI and reached a plateau 10 days later (Fig. 3 ), but because of newly synthesized cardiac AC protein, the amount VI limited sample size at each time point, we emphasize that remaining 1, 2 and 3 days after reinstitution of suppression these are estimates.
was 96, 71 and 38%, respectively (Fig. 4) . These data Fig. 6 ). Basal cAMP levels were unchanged, as previously reported in examples in which AC was VI expressed in normal heart or in normal cardiac myocytes [7, 10] . We have previously reported that increasing the amounts of cardiac AC is not associated with alterations VI in myocardial b-adrenergic receptor number or in the amounts of Gia2 or Gsa [7, 9] . Hearts isolated from the two groups showed similar basal heart rates (Transgene Off: 231626 bpm, n54; Transgene On: 245617 bpm, n54; P50.67) and basal LV dP/dt ( Fig. 6; P50.31) . However, hearts isolated from animals that had transgene suppression removed showed marked increases in left ventricular dP/dt in response to dobutamine infusion (P50.009; n54 for each group; Fig.  6 ). These data indicate that regulated expression of cardiac AC is functionally important, coupled and recruitable VI through b-adrenergic receptor stimulation. when activated, was rapidly reversed when suppression was reapplied, and expression was limited to the heart.
Of the six transgenic lines that were positive for the provide an estimated half-life of newly synthesized AC transgene, two lines showed transgene expression upon VI of 2-3 days. We found that in the constitutively expressed activation, while four lines did not. This is likely due to the cardiac-directed AC transgenic mouse, expression of integration site of the transgene expression cassette within VI cardiac AC appears to be unchanged (Fig. 5A ). the chromosome [11] . The lack of expression in four of the V lines may be due to the integration of the transgene 3 .5. Tissue-specific regulation and expression expression cassette in an area subjected to a silencer effect [12] . Thus, due to the variability observed between transTranscription of transgene AC was restricted to the genic lines, screening of a high number of transgenic VI heart. Northern blot analysis showed that there was no animals may be required to obtain an adequate induction of expression of transgene AC message in brain, kidney, the transgene. On the other hand, once an inducible line VI liver, lung, skeletal muscle and spleen (Fig. 5B) . These was obtained, the transgene cassette was efficiently transdata indicate that cardiac-directed expression of tTA and mitted from generation to generation (so far, up to seven lack of leakage of AC expression from TRE.CMV.min generations), showing that the transgenic line was stable VI promoter provides cardiac-specific expression. over time.
In the tet-off transgenic line generated in this study, 3 .6. Functional assessment of regulated transgene AC protein levels were induced 10-fold over endogenous VI AC levels 10 days after removal of doxycycline. Isolated
VI
To determine whether controlled expression of cardiaccardiac myocytes from these animals showed increased directed AC could lead to important functional consecAMP production in response to isoproterenol and for-VI quences, we measured cAMP production in isolated carskolin stimulation and their hearts showed marked indiac myocytes and left ventricular pressure development in creases in left ventricular pressure development during isolated perfused hearts. Regulated expression of cardiacb-adrenergic receptor stimulation. We have previously production and an enhanced responsiveness of the heart to provided an opportunity to assess the biological half-life of stress [7] . Furthermore, in a somatic gene transfer study, AC . Taking advantage of the fact that we could rapidly VI we showed that cardiac responsiveness is increased even and completely suppress the expression of transgene AC , VI when cardiac AC is increased 2-fold [13] . Thus, the we showed that newly synthesized AC has an approxi-VI VI magnitude of induction observed in our cardiac-specific, mate half-life in the heart of 2-3 days. tet-off AC transgenic mice should be sufficient to The transgenic construct was generated such that the VI achieve a therapeutic effect in the setting of heart failure. expression of the transactivator (tTA), which provides We also demonstrated the reversibility of AC inductet-regulated expression, is under the control of the car-VI tion: newly synthesized cardiac AC protein was substandiac-specific aMHC promoter. This feature should allow VI tially reduced 3 days after the addition of doxycycline. constitutive expression of tTA in the heart only. In the Activation of transgene expression combined with rapid heart, tTA should interact with the tet operon placed suppression is an advantageous characteristic of the regulaupstream the AC transgene, and thereby provide a tet-VI tion system that would be useful to test the therapeutic regulated, cardiac-specific expression of the transgene. We effect of AC transgene in a heart failure model. If the demonstrated that, indeed, AC transgene expression was VI VI transgene proves to have a therapeutic effect on heart restricted to the heart tissues, as no transgene expression failure, then turning-off transgene expression should result was detected in other tissues. In another study using a in a return of signs of heart failure. similar transgenic construct, transgene (luciferase) expresBecause of inability of available antibodies specific for sion was also induced in the lungs [5] . The lack of AC to precipitate the protein, pulse labeling studies have specificity of the aMHC promoter could explain this analysis. Studies were conducted on tissues obtained from two transgene positive siblings (Mouse 1 and Mouse 2) after removal of doxycycline. Transgene expression was easily detectable in heart, but was undetectable in other organs. Equivalent RNA loading was confirmed by 18S and 28S band size. h, heart; b, brain; k, kidney; l, liver; lu, lung; m, skeletal muscle; s, spleen. observation; indeed, the aMHC promoter has been shown (HKH, DMR) and American Heart Association Western to yield low level of expression in noncardiac tissues in a States Affiliate Postdoctoral Fellowship Award 0020064Y transgenic setting [14] .
(HB) supported this research. An important limitation to standard crossbreeding paradigms examining the effects of potential therapeutic transgenes in treating genetic models of heart failure is that R eferences the therapeutic transgene is present prior to the development of heart failure. This model will facilitate experi-
